UNSPSC 51294602: Pipofezine

This classification denotes an antidepressant agent with the molecular formula C16H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8T739L1FA, chemically known as 5-methyl-3-(4-methyl-1-piperazinyl)-5h-pyridazino(3,4-b)(1,4)benzoxazine but generally known as pipofezine, which bears US NIH Compound Identifier 159977. European Medicines Agency schedules Pipofezine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09877MIG. The term PIPOFEZINE is an International Non-Proprietary Name.

UNSPSC 51294602 Pipofezine is a Commodity code that does not align with recent state and local procurement activity. The three most recent opportunities posted under or near this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which match the nominal scope of pipofezine, a specific pharmaceutical compound. The mismatch suggests that state and local jurisdictions are either tagging opportunities inconsistently or that this code sees minimal relevant recent activity in the current procurement marketplace.

The recent opportunities that do appear under or adjacent to this code involve Seminole County, Florida purchasing naloxone and drug deactivation systems through an IFB (solicitation IFB60459723LAS, due July 26, 2023), the Texas Health and Human Services Commission issuing an RFI on direct-to-manufacturer pharmacy programs (HHS0017013, posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posting an RFP for generic pharmaceuticals and OTC products (S1070000015802, due March 26, 2026). These solicitations span health agencies, cooperative purchasing vehicles, and multi-state participation but do not represent a coherent pipeline for pipofezine procurement. Without evidence of current or planned pipofezine-specific opportunities, this code does not support a focused business development strategy at this time.